Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03267654

Recruitment Status : Recruiting

First Posted : August 30, 2017

Last Update Posted : August 3, 2020

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Qilu Pharmaceutical Co., Ltd.

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	October 20, 2020
Estimated Study Completion Date :	December 30, 2021

To Top